timothy sykes logo
TENX Stock Whipsaws As Traders Target Volatile Setup Thumbnail
G Google News

TENX Stock Whipsaws As Traders Target Volatile Setup

TIM SYKES•UPDATED AUG. 10, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Tenax Therapeutics Inc. faces heightened downside risk as critical clinical trial setbacks dominate sentiment, with stocks have been trading down by -85.99 percent.

Key Takeaways

  • TENX has pulled back from late-July highs above $16, grinding lower into the mid‑$13s while still holding a wide intraday range.
  • The latest TENX quarter shows heavy cash burn and a net loss of about $17.8M, typical of an early-stage biotech trying to push drugs forward.
  • Tenax Therapeutics Inc. carries roughly $118M in cash and minimal liabilities, giving traders confidence the company can fund operations near term.
  • Intraday tape on TENX shows a violent premarket flush from the $12s into the $2s, underscoring extreme volatility and liquidity traps.
  • With high cash, negative earnings, and big swings, TENX sits squarely in the high-risk, high-reward biotech trading bucket.

Candlestick Chart

Live Update At 09:18:52 EDT: On Monday, August 10, 2026 Tenax Therapeutics Inc. stock [NASDAQ: TENX] is trending down by -85.99%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tenax Therapeutics Inc., ticker TENX, trades like a classic small-cap biotech: ugly earnings, huge cash pile, and wild price swings. The latest quarterly report for TENX shows revenue is essentially not the story; this is a development-stage name burning money to chase future approvals.

TENX posted a net loss of about $17.8M for the quarter, or roughly -$0.35 per share. Operating expenses near $18.8M were driven mostly by research and development of around $12.8M, with general and administrative costs near $5.9M. That tells traders the company is plowing most of its spending into the science, not overhead.

On the balance sheet, TENX lists about $121.7M in total assets and only about $8.1M in liabilities. Cash and restricted cash are roughly $118M, producing a hefty current ratio above 15. For traders, that means runway: Tenax Therapeutics Inc. is losing money, but it is not staring down a liquidity wall tomorrow.

More Breaking News

Return metrics are deeply negative, with return on equity near -53% and return on assets around -57%. That is normal in this space, but it confirms TENX is purely a speculation on future success, not a cash machine today.

Why Traders Are Watching TENX Price Action

The real story for TENX right now is the chart. On the daily timeframe, Tenax Therapeutics Inc. has faded from a late‑July push into the $16 area down toward the low‑to‑mid $13s. That is a meaningful retrace, but not a total breakdown. Highs have been slipping while lows stay choppy, creating a short-term downtrend inside a still-wide trading range.

For active traders, that kind of structure can become a springboard. TENX is no sleepy value name; it is a potential momentum vehicle. The daily candles show repeated tests of the mid‑teens, followed by quick rejections. Each bounce attempt around $15–$16 has been sold, signaling profit-taking and possibly short pressure stepping in. At the same time, dips into the low‑$13s have found buyers so far, hinting at a developing support zone.

The intraday 5‑minute tape is even more intense. Premarket prints show TENX trading in the $12–$13 area, then collapsing in one massive move down into the $2s. That type of cliff dive usually comes from reverse splits, halts, or sudden repricing. For day traders, it means slippage and risk of being trapped if they chase.

After that flush, TENX chopped between about $1.80 and $2.10, showing it still has enough volume for fast scalps, but every entry must be planned. Tenax Therapeutics Inc. is now a stock where a few cents of spread matter, and where liquidity can vanish on a single candle. This is the definition of a “trade the price, not the story” setup.

Conclusion

TENX sits at the crossroads of three forces that every small-cap biotech trader knows well: ugly earnings, strong cash, and violent charts. Tenax Therapeutics Inc. is burning around $14.2M in operating cash per quarter, but it also holds roughly $118M in cash and restricted cash with very little debt. That combination gives the company time, which in this game means optionality — more runway for trials, updates, and potential future catalysts.

On the screen, though, runway does not equal safety. TENX has already shown it can drop from the teens into the low single digits in a heartbeat. Daily lower highs, a sliding close from above $16 to around $13–$14, and that brutal intraday flush all tell traders the same thing: this is a battlefield stock. Risk management is not optional here; it is the whole game. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” In a name like TENX, that mindset about protecting trading capital matters more than chasing every spike.

For traders who study Tenax Therapeutics Inc., the edge comes from preparation — mapping support and resistance, sizing small enough to survive surprises, and respecting the stock’s personality. As Tim Sykes likes to hammer home, “The market doesn’t care about your opinion, it rewards preparation and punishes ignorance.” TENX is a live example of that rule. Study the filings, track the price action, and treat every trade as a lesson, not a lottery ticket.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”